| id |
ndltd-NEU--neu-776
|
| record_format |
oai_dc
|
| spelling |
ndltd-NEU--neu-7762021-05-26T05:10:40ZDesign and synthesis of adenosine receptor antagonist bioconjugates as anti-tumor immunotherapiesIstradefylline (KW-6002) is one of many xanthines that act as antagonists of the A2A adenosine receptor (A2AR). While this molecule has recently been involved in phase III clinical trials as a target therapeutic for Parkinson's disease, its target pathway also implicated in tumorigenesis. As was described by Ohta et al, the oxygen-deprived hypoxic tumor microenvironment fosters increased production of adenosine, which up-regulates formation of cAMP following binding to the A2A receptor. Increased intracellular levels of cAMP are responsible for immunosuppression and misguided protection of cancerous cells. KW-6002 has shown efficacy in rescuing T-cell regulatory function in models of adoptive transfer immunotherapy.http://hdl.handle.net/2047/D20001031
|
| collection |
NDLTD
|
| sources |
NDLTD
|
| description |
Istradefylline (KW-6002) is one of many xanthines that act as antagonists of the A2A adenosine receptor (A2AR). While this molecule has recently been involved in phase III clinical trials as a target therapeutic for Parkinson's disease, its target pathway also implicated in tumorigenesis. As was described by Ohta et al, the oxygen-deprived hypoxic tumor microenvironment fosters increased production of adenosine, which up-regulates formation of cAMP following binding to the
A2A receptor. Increased intracellular levels of cAMP are responsible for immunosuppression and misguided protection of cancerous cells. KW-6002 has shown efficacy in rescuing T-cell regulatory function in models of adoptive transfer immunotherapy.
|
| title |
Design and synthesis of adenosine receptor antagonist bioconjugates as anti-tumor immunotherapies
|
| spellingShingle |
Design and synthesis of adenosine receptor antagonist bioconjugates as anti-tumor immunotherapies
|
| title_short |
Design and synthesis of adenosine receptor antagonist bioconjugates as anti-tumor immunotherapies
|
| title_full |
Design and synthesis of adenosine receptor antagonist bioconjugates as anti-tumor immunotherapies
|
| title_fullStr |
Design and synthesis of adenosine receptor antagonist bioconjugates as anti-tumor immunotherapies
|
| title_full_unstemmed |
Design and synthesis of adenosine receptor antagonist bioconjugates as anti-tumor immunotherapies
|
| title_sort |
design and synthesis of adenosine receptor antagonist bioconjugates as anti-tumor immunotherapies
|
| publishDate |
|
| url |
http://hdl.handle.net/2047/D20001031
|
| _version_ |
1719406419733643264
|
